BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21793038)

  • 1. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.
    Rockenstein E; Ubhi K; Pham E; Michael S; Doppler E; Novak P; Inglis C; Mante M; Adame A; Alvarez XA; Moessler H; Masliah E
    J Neurosci Res; 2011 Nov; 89(11):1812-21. PubMed ID: 21793038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.
    Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E
    J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease.
    Ubhi K; Rockenstein E; Vazquez-Roque R; Mante M; Inglis C; Patrick C; Adame A; Fahnestock M; Doppler E; Novak P; Moessler H; Masliah E
    J Neurosci Res; 2013 Feb; 91(2):167-77. PubMed ID: 23152192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.
    Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E
    Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.
    Rockenstein E; Mallory M; Mante M; Alford M; Windisch M; Moessler H; Masliah E
    J Neural Transm Suppl; 2002; (62):327-36. PubMed ID: 12456076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.
    Ubhi K; Rockenstein E; Doppler E; Mante M; Adame A; Patrick C; Trejo M; Crews L; Paulino A; Moessler H; Masliah E
    Acta Neuropathol; 2009 Jun; 117(6):699-712. PubMed ID: 19252918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.
    Masliah E; Armasolo F; Veinbergs I; Mallory M; Samuel W
    Pharmacol Biochem Behav; 1999 Feb; 62(2):239-45. PubMed ID: 9972690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xestospongin C, a Reversible IP3 Receptor Antagonist, Alleviates the Cognitive and Pathological Impairments in APP/PS1 Mice of Alzheimer's Disease.
    Wang ZJ; Zhao F; Wang CF; Zhang XM; Xiao Y; Zhou F; Wu MN; Zhang J; Qi JS; Yang W
    J Alzheimers Dis; 2019; 72(4):1217-1231. PubMed ID: 31683484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
    Rockenstein E; Adame A; Mante M; Larrea G; Crews L; Windisch M; Moessler H; Masliah E
    J Neural Transm (Vienna); 2005 Feb; 112(2):269-82. PubMed ID: 15657642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury.
    Zhang Y; Chopp M; Meng Y; Zhang ZG; Doppler E; Winter S; Schallert T; Mahmood A; Xiong Y
    J Neurosurg; 2015 Apr; 122(4):843-55. PubMed ID: 25614944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice.
    Wu M; Shi H; He Y; Yuan L; Qu X; Zhang J; Wang Z; Cai H; Qi J
    J Alzheimers Dis; 2017; 59(3):1067-1078. PubMed ID: 28731445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.
    Zhang W; Zhang W; Li Z; Hao J; Zhang Z; Liu L; Mao N; Miao J; Zhang L
    Pharmacol Biochem Behav; 2012 Jan; 100(3):361-9. PubMed ID: 21993310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice.
    Yin K; Jin J; Zhu X; Yu L; Wang S; Qian L; Han L; Xu Y
    Neurol Res; 2017 Oct; 39(10):885-894. PubMed ID: 28743230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.
    Li T; Jiao JJ; Hölscher C; Wu MN; Zhang J; Tong JQ; Dong XF; Qu XS; Cao Y; Cai HY; Su Q; Qi JS
    Hippocampus; 2018 May; 28(5):358-372. PubMed ID: 29473979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice.
    Wiley JC; Pettan-Brewer C; Ladiges WC
    Aging Cell; 2011 Jun; 10(3):418-28. PubMed ID: 21272191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
    Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
    Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
    Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
    J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.
    Doppler E; Rockenstein E; Ubhi K; Inglis C; Mante M; Adame A; Crews L; Hitzl M; Moessler H; Masliah E
    Acta Neuropathol; 2008 Oct; 116(4):425-37. PubMed ID: 18600331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.